883-92-1

Basic information

• Product Name: 6-CHLORO-2-OXO-2H-CHROMENE-3-CARBOXYLIC ACID
• Synonyms: 6-Chloro-2-oxo-2H-chromene-3-carboxylic acid ,95%;6-chloro-2-oxo-2H-chromene-3-carboxylic acid(SALTDATA: FREE);6-chloro-2-keto-chromene-3-carboxylic acid;6-chloro-2-oxo-3-chromenecarboxylic acid;6-chloro-2-oxo-chromene-3-carboxylic acid;6-chloro-2-oxochromene-3-carboxylic acid;6-chloro-2-oxo-2H-1-Benzopyran-3-carboxylic acid;TIMTEC-BB SBB004435
• CAS NO: 883-92-1
• Molecular Formula: C₁₀H₅ClO₄
• Molecular Weight: 224.6
• EINECS: 145-458-8
• Mol File: 883-92-1.mol
• Article Data: 3

Chemical Properties

• Melting Point: 193 °C(Solv: ethanol (64-17-5))
• Boiling Point: 426.5 °C at 760 mmHg
• Flash Point: 211.7 °C
• Appearance: /
• Density: 1.612 g/cm³
• Vapor Pressure: 4.93E-08mmHg at 25°C
• Refractive Index: 1.649
• PKA: 1.51±0.20(Predicted)
• CAS DataBase Reference: 6-CHLORO-2-OXO-2H-CHROMENE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-2-OXO-2H-CHROMENE-3-CARBOXYLIC ACID(883-92-1)
• EPA Substance Registry System: 6-CHLORO-2-OXO-2H-CHROMENE-3-CARBOXYLIC ACID(883-92-1)

Safety Data

• Hazard Codes: Xi
• Statements: 34
• Safety Statements: 26-36/37/39-45
• HazardClass: IRRITANT
• Hazardous Substances Data: 883-92-1(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C10H5ClO4/c11-6-1-2-8-5(3-6)4-7(9(12)13)10(14)15-8/h1-4H,(H,12,13)

Upstream product

• 2420-26-0 4-chlorosalicylaldehyde 
• 2033-24-1 cycl-isopropylidene malonate 

Downstream Products

• 72973-49-0 6-chlorocoumarin-3-carboxylic acid 
• 1366125-57-6 C₁₇H₁₃ClO₃S 

Relevant articles and documents

Novel coumarin-thiazolyl ester derivatives as potential DNA gyrase Inhibitors: Design, synthesis, and antibacterial activity

The design and synthesis of novel coumarin-thiazolyl ester derivatives of potent DNA gyrase inhibitory activity were the main aims of this study. All the novel synthesized compounds were examined for their antibacterial activity against Staphylococcus aureus, Listeria monocytogenes, Escherichia coli and Salmonella. Compound 8p exhibited excellent antibacterial activity against four bacteria strains with MIC values of 0.05, 0.05, 8, and 0.05 μg/mL, respectively. In vitro drug-resistant bacterial inhibition experiments indicated that compound 8p exhibited the best bacteriostatic effect in the selected compounds and four positive control drugs with MIC values of 4 μg/mL. In vitro enzyme inhibitory assay showed that compound 8p exhibited potent inhibition against DNA gyrase with IC50 values of 0.13 μM. The molecular docking model indicated that compounds 8p can bind well to the DNA gyrase by interacting with amino acid residues. This study demonstrated that the compound 8p can act as the most potent DNA gyrase inhibitor in the reported series of compounds and provide valuable information for the commercial DNA gyrase inhibiting bactericides.

Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity

The identification of novel Topoisomerase II (Topo II) inhibitors is one of the most attractive directions in the field of bactericide research and development. In our ongoing efforts to pursue the class of inhibitors, six series of 70 novel coumarin-pyrazole carboxamide derivatives were designed and synthesized. As a result of the evaluation against four destructive bacteria, including Staphylococcus aureus, Listeria monocytogenes, Escherichia coli and Salmonella. Compound 8III-k (MIC = 0.25 mg/L) showed considerable inhibitory activity than ciprofloxacin (MIC = 0.5 mg/L) against Escherichia coli and 8V-c (MIC = 0.05 mg/L) exhibited excellent antibacterial activity than ciprofloxacin (MIC = 0.25 mg/L) against Salmonella. The selected compounds (8III-k, 8V-c and 8V-k) exhibit potent inhibition against Topo II and Topo IV with IC50 values (9.4–25 mg/L). Molecular docking model showed that the compounds 8V-c and 8V-k can bind well to the target by interacting with amino acid residues. It will provide some valuable information for the commercial Topo II inhibiting bactericides.